



AKADEMISKA
SJUKHUSET



UPPSALA
UNIVERSITET

Fast and Reliable 16S Diagnostics for Prosthetic joint Infections

Validation of an Oxford Nanopore-Based 16S rRNA Gene Sequencing Method for Rapid Bacterial Identification in Foreign Body and Sterile Site Infections

Susanna Thyselius¹, Ida Karlsson^{2,4}, Sofia Persson¹, Mats Lindeborg¹, Martina Cederblom¹, René Kaden^{1,2}, Patrik Ellström^{1,3}

¹ Clinical Microbiology, Uppsala University Hospital, Sweden ² Clinical Genomics Uppsala, Science for Life Laboratory, Uppsala University, Sweden


³ Zoonosis Science Center, Department of Medical Sciences, Uppsala University, Sweden ⁴Department och Immunology, Genetics and Pathology, Uppsala University, Sweden

Summary

An in-house Oxford Nanopore Technology (ONT) based full length 16S gene sequencing workflow was validated against culture and Sanger sequencing, across five different criteria for significant findings. A commercial spike-in control improved interpretation and contamination detection. Ligation-based barcoding allowed co-sequencing of multiple amplicons from different assays to be sequenced on the same flow cell, increasing time- and cost-efficiency.

Background

ONT sequencing enables analysis of the full-length 16S gene which improves species identification.



For adequate diagnostics, criteria are needed to distinguish true pathogens from background signals and contaminating flora. We aimed to validate an ONT-based 16S gene sequencing workflow by systematically comparing criteria for defining significant pathogen levels and addressing challenges in distinguishing clinically relevant organisms.

A secondary aim was to develop a rapid, scalable workflow enabling co-sequencing of 16S with other PCR amplicons, making it suitable for laboratories that do not fill an entire flow cell with each run.

Evaluated criteria for a True Positive Finding

Baseline requirements

A species must have ≥ 50 reads to be considered a positive finding.


Five sets of criteria were evaluated

- 1) RA* $\geq 5\%$ AND total no. of reads > 1000
- 2) RA $\geq 2,5\%$ AND total no. of reads > 1000
- 3) RA $\geq 1\%$ AND total no. of reads > 1000
- 4) RA $\geq 1\%$ AND result invalid if $\geq 90\%$ of reads unassigned
- 5) RA $\geq 2,5\%$ AND result invalid if $\geq 90\%$ reads unassigned (*Relative Abundance)


Corresponding author:

Patrik Ellström: patrik.ellstrom@medsci.uu.se

Nanopore vs Culture



Nanopore vs Culture




Criteria for significant pathogen


- >5% and >100 reads
- >2,5% and >1000 reads
- >1% and >1000 reads
- >1% and <90% unassigned
- >2,5% and <90% unassigned




Nanopore vs Sanger



Nanopore vs Sanger



Nanopore vs Culture or Sanger



Nanopore vs Culture or Sanger



12 sonicates analyzed with and without a spike-in control and results compared to Sanger sequencing and/or culture diagnostics for each criteria.

Results

Concordance between our Nanopore 16S method and the two comparison methods varied across evaluated criteria from 87% to 95% for sonicated implants and from 55% to 83% for tissues.

Incorporating a **spike in control** improved concordance to 100% for sonicates and 83% to 89% for tissues, and greatly aided results interpretation.

Limit of detection in tissue samples spiked with bacterial mixture was $2-8 \times 10^2$ CFU per species, except for *S. aureus* which required $6-7 \times 10^3$ CFU.

Final criteria for true positives

A species is accepted only if

- ≥ 50 reads
- Relative Abundance $\geq 1\%$
- > 1000 total reads in the sample

Conclusions:

Applying thresholds for defining clinically significant pathogen levels and the use of a multi-species process control substantially improved results interpretation and inter assay stability control in clinical 16S analyses of prosthetic joint infections.

Materials and methods

A total of 87 sonicated prosthetic implants and 18 tissue samples from suspected foreign-body infections were included. 12 sonicates and all tissue samples were also processed with and without a commercial spike-in control to assess PCR inhibition.

Samples were homogenised, pretreated with mutanolysin and DNA extracted using MagDEA Dx SV. Duplicate PCR was performed with primers 27F/1492R and amplicons were barcoded with the ONT Native Barcoding Kit (v14) and sequenced on a GridION platform.

Bioinformatics analysis was performed in Geneious Prime using Emu for species identification (workflow available at: https://github.com/clinical-genomics-uppsala/Geneious_metabarcoding).

The Limit of Detection (LOD) was evaluated using tissue samples spiked with a defined bacterial mock community.

All criteria were compared with Sanger sequencing and culture based diagnostics.

REGION UPPSALA